Hypoglycemia - Pipeline Review, H2 2018

  • ID: 4592422
  • Drug Pipelines
  • 78 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Adocia SAS
  • Arecor Ltd
  • Eli Lilly and Co
  • Heptares Therapeutics Ltd
  • Novartis AG
  • Rezolute Inc
  • MORE
Hypoglycemia - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H2 2018, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

Report Highlights:

This latest pipeline guide Hypoglycemia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 6, 5 and 2 respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adocia SAS
  • Arecor Ltd
  • Eli Lilly and Co
  • Heptares Therapeutics Ltd
  • Novartis AG
  • Rezolute Inc
  • MORE
Introduction

Report Coverage

Hypoglycemia - Overview

Hypoglycemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoglycemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoglycemia - Companies Involved in Therapeutics Development

Adocia SAS

Arecor Ltd

Eiger BioPharmaceuticals Inc

Eli Lilly and Co

Heptares Therapeutics Ltd

LATITUDE Pharmaceuticals Inc

Novartis AG

Rezolute Inc

Therakind Ltd

USV Pvt Ltd

XERIS Pharmaceuticals Inc

Zealand Pharma AS

Zucara Therapeutics Inc

Hypoglycemia - Drug Profiles

dasiglucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exendin-(9-39) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3143753 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3185643 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-900018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRL-2903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RZ-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoglycemia - Dormant Projects

Hypoglycemia - Discontinued Products

Hypoglycemia - Product Development Milestones

Featured News & Press Releases

Jun 25, 2018: Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen

Jun 23, 2018: Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

Jun 08, 2018: Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes

May 28, 2018: Zealand Pharma reports completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia

Apr 11, 2018: Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon

Apr 10, 2018: Data from Lilly Real-World Use Study Designed to Evaluate Moderate or Severe Hypoglycemia Treatment Published in Pediatric Diabetes Journal

Mar 26, 2018: Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia

Mar 20, 2018: Zealand Pharma's first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objective

Feb 21, 2018: Zealand Pharma reports completion of the first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia

Feb 15, 2018: Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia

Feb 08, 2018: FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH)

Jan 19, 2018: Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018

Dec 07, 2017: Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes

Nov 20, 2017: Adocia Reports Top line Results of BioChaperone Glucagon Phase 1 Study

Sep 21, 2017: JDRF Funds Zucara Therapeutics' Approach to Preventing Hypoglycemia in People with Type 1 Diabetes

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hypoglycemia, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hypoglycemia - Pipeline by Adocia SAS, H2 2018

Hypoglycemia - Pipeline by Arecor Ltd, H2 2018

Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H2 2018

Hypoglycemia - Pipeline by Eli Lilly and Co, H2 2018

Hypoglycemia - Pipeline by Heptares Therapeutics Ltd, H2 2018

Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2018

Hypoglycemia - Pipeline by Novartis AG, H2 2018

Hypoglycemia - Pipeline by Rezolute Inc, H2 2018

Hypoglycemia - Pipeline by Therakind Ltd, H2 2018

Hypoglycemia - Pipeline by USV Pvt Ltd, H2 2018

Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H2 2018

Hypoglycemia - Pipeline by Zealand Pharma AS, H2 2018

Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H2 2018

Hypoglycemia - Dormant Projects, H2 2018

Hypoglycemia - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Hypoglycemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adocia SAS
  • Arecor Ltd
  • Eiger BioPharmaceuticals Inc
  • Eli Lilly and Co
  • Heptares Therapeutics Ltd
  • LATITUDE Pharmaceuticals Inc
  • Novartis AG
  • Rezolute Inc
  • Therakind Ltd
  • USV Pvt Ltd
  • XERIS Pharmaceuticals Inc
  • Zealand Pharma AS
  • Zucara Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll